Neuroendocrine liver metastases often require multiple modes of treatment to attain disease control, which can utilize various forms of radiolabelled agents either delivered systemically or preferentially towards the liver. A recent trial suggested both safety and efficacy of a novel approach of combining the two to provide a radiation ‘boost’ to hepatic deposits.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Frilling, A. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 15, e8–21 (2014).
Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017).
Chen, J. X. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc. Intervent. Radiol. 40, 69–80 (2017).
Kratochwil, C. et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr. Relat. Cancer 18, 595–602 (2011).
Kennedy, A. et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB 17, 29–37 (2015).
Frilling, A. et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB 21, 773–783 (2019).
Braat, A. J. A. T. et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 21, 561–570 (2020).
Strosberg, J. et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
Pavel, M. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103, 172–185 (2016).
Kennedy, A. et al. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: Expert consensus. J. Gastrointest. Oncol. 8, 1079–1099 (2017).
A.F. reports receiving speaker honoraria from SIRTEX. A.K.C. declares no competing interests.
About this article
Cite this article
Frilling, A., Clift, A.K. Combining radiolabelled therapies for neuroendocrine neoplasms. Nat Rev Endocrinol 16, 347–348 (2020). https://doi.org/10.1038/s41574-020-0367-3